Recall sparks shortage

Sanofi-Aventis has notified the TGA that the tablet form of its vigabatrin product, Sabril, is in shortage The Therapeutic Goods Administration has said in a statement that the shortage has been triggered by a global recall. It is expected to last until 30 September 2023. The oral 500 mg powder sachet form of the product